Tag: Diabetes: Type II
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them
Certain Combinations of Food Additives May Increase Risk for Type 2 Diabetes
Authors say limiting certain food additives may be an effective public health strategy to prevent diabetes
Tirzepatide Dispensations Increased Rapidly After Approval
By December 2023, 12.3 percent of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide
ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes
Minimal TV Viewing May Cut ASCVD Risk in Those With T2DM Genetic Risk
Medium and high T2DM genetic risk not linked to increased risk for ASCVD when TV viewing is no more than one hour/day
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin
Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors
Sotagliflozin can also significantly reduce the rate of myocardial infarction and stroke compared with placebo
Nonarteritic Anterior Ischemic Optic Neuropathy Increased With Semaglutide
Increase in NAION associated with semaglutide use among individuals with type 2 diabetes
Probability of Cardiovascular Events Lower in Type 1 Diabetes Versus Type 2
Type 1 diabetes associated with less myocardial infarction, percutaneous coronary intervention, stroke, and limb ischemia
